Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?

Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?

There is a new generation of antiobesity drugs in development or just arriving on the scene. First, setmelanotide has been approved for three of the ultrarare genetic conditions that cause obesity–#8211;pro-opiomelanocortin deficiency, proprotein convertase subtilisin and kexin type 1 (an important...

Full description

Bibliographic Details
Main Author:	Donna H. Ryan
Format:	Article
Language:	English
Published:	Korean Society for the Study of Obesity 2021-09-01
Series:	Journal of Obesity & Metabolic Syndrome
Subjects:	anti-obesity agents anti-obesity drugs weight loss agents setmelanotide semaglutide tirzepatide bimagrumab
Online Access:	http://journaleditor.inforang.com/journal/view.html?doi=10.7570/jomes21033

Similar Items

Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency
by: Tinh-Hai Collet, et al.
Published: (2017-10-01)

The Discovery and Development of Liraglutide and Semaglutide
by: Lotte Bjerre Knudsen, et al.
Published: (2019-04-01)

Does intervention with GLP-1 receptor agonist semaglutide modulate perception of sweet taste in women with obesity: study protocol of a randomized, single-blinded, placebo-controlled clinical trial
by: Mojca Jensterle, et al.
Published: (2021-07-01)

Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes?
by: Hwi Seung Kim, et al.
Published: (2021-09-01)

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
by: Mansoor Husain, et al.
Published: (2020-09-01)

Two Cases With an Early Presented Proopiomelanocortin Deficiency—A Long-Term Follow-Up and Systematic Literature Review
by: Nadan Gregoric, et al.
Published: (2021-06-01)

Anti-Obesity Drugs: A Review about Their Effects and Safety
by: Jun Goo Kang, et al.
Published: (2012-02-01)

Semaglutide-associated bullous pemphigoid
by: Clayton P. Burruss, BS, et al.
Published: (2021-09-01)

Effects of the Topical Administration of Semaglutide on Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes
by: Rafael Simó, et al.
Published: (2021-07-01)

Clinical potential of treatment with semaglutide in type 2 diabetes patients
by: Michael E Røder
Published: (2019-12-01)

Safety of Semaglutide
by: Mark M. Smits, et al.
Published: (2021-07-01)

Diets and drugs for weight loss and health in obesity – An update
by: Jan Aaseth, et al.
Published: (2021-08-01)

Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy
by: Gomez-Peralta F, et al.
Published: (2019-02-01)

Advances in GLP-1 treatment: focus on oral semaglutide
by: Freddy G. Eliaschewitz, et al.
Published: (2021-09-01)

Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date
by: Pearson S, et al.
Published: (2019-12-01)

An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain
by: Santiago Tofé, et al.
Published: (2021-03-01)

Can sibutramine alter systemic blood pressure in obese patients? Systematic review and meta-analysis
by: Hernani Pinto de Lemos Júnior, et al.

More Unnecessary Imaginary Worlds – Part 2: The ICER Evidence Report on Modeling Oral Semaglutide for Type 2 Diabetes
by: Paul Langley
Published: (2020-02-01)

Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide
by: Baptist Gallwitz, et al.
Published: (2021-06-01)

Species Differences in Stereoselective Pharmacokinetics of HSG4112, A New Anti-Obesity Agent
by: In Yong Bae, et al.
Published: (2020-02-01)

Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis
by: Ping Zhong, et al.
Published: (2021-10-01)

Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis
by: Hassan A. Alsugair, et al.
Published: (2021-08-01)

Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes
by: Xin Zhang, et al.
Published: (2021-07-01)

Oxintomodulina e obesidade Oxyntomodulin and obesity
by: Gustavo Duarte Pimentel, et al.
Published: (2009-10-01)

Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6
by: Michael A. Nauck, et al.
Published: (2021-03-01)

Pengaruh moderate intensity continuous exercise terhadap kadar irisin serum pada wanita remaja obesitas
by: Ido Nur Abdulloh, et al.
Published: (2021-02-01)

Systemic Antibiotics and Obesity: Analyses from a Population-Based Cohort
by: So Young Park, et al.
Published: (2021-06-01)

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
by: Juris J. Meier
Published: (2021-06-01)

Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China
by: Shanshan Hu, et al.
Published: (2021-06-01)

Acute Kidney Injury Associated With Semaglutide
by: David J. Leehey, et al.
Published: (2021-03-01)

Editorial: Reviews and Novel Clinical Perspectives on Semaglutide: A GLP-1 Receptor Agonist With Both Injectable and Oral Formulations
by: Juris J. Meier, et al.
Published: (2021-09-01)

Cardiovascular Risks and Benefits of Medications Used for Weight Loss
by: Carolyn T. Bramante, et al.
Published: (2020-01-01)

Commentary: Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy
by: Javier Durán, et al.
Published: (2018-04-01)

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
by: Lawrence A. Leiter, et al.
Published: (2019-06-01)

New ideas about the pathogenesis of osteoarthritis, the role of metabolic disorders
by: Lyudmila I. Alekseeva
Published: (2019-09-01)

Dietary GABA and its combination with vigabatrin mimic calorie restriction and induce antiobesity-like effects in lean mice
by: Kanako Sato, et al.
Published: (2021-03-01)

Uso de drogas antiobesidade entre estudantes universitários Use of anti-obesity drugs among college students
by: Maria do Carmo de Carvalho e Martins, et al.
Published: (2011-10-01)

Obesity Drug Update: The Lost Decade?
by: Fayi Yao, et al.
Published: (2010-11-01)

Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Fang-Hong Shi, et al.
Published: (2018-06-01)

A study of the rabbit eye test system to determine the activity of acidic non-steroidal anti-inflammatory agents
by: Wiseman, Ian Charles
Published: (1977)